Highest-materiality recent filing
Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50
Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.
Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul
Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.
Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.
Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance
Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.
Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY
Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.
Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026
Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.
Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%
Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).
Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.
Integra LifeSciences receives FDA warning letter for quality system violations at three facilities
FDA warning letter dated Dec 19, 2024, for quality system issues at Mansfield, MA; Plainsboro, NJ; Princeton, NJ facilities.
Integra LifeSciences names Mojdeh Poul as President & CEO effective Jan 6, 2025
Mojdeh Poul appointed President & CEO, effective January 6, 2025, succeeding Jan De Witte.
Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO
Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.
Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds
GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.
Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent
Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.
On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
On November 4, 2024, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Mojdeh Poul to serve as its President and Chief Executive Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings